Express Diagnostics Int'l, Inc. Appoints Blinded Diagnostics to offer Drugs of Abuse and Alcohol Testing for use in Pharmaceutical Clinical Trials

Express Diagnostics Int'l, Inc.  Appoints Blinded Diagnostics to offer Drugs of Abuse and Alcohol Testing for use in Pharmaceutical Clinical Trials

Saddle Brook, NJ, Dec 6, 2012:  Blinded Diagnostics today announced the expansion of their diagnostic product portfolio with the addition of an extensive line of screening tests for drugs of abuse and alcohol from Express Diagnostics Int'l, Inc. (EDI) of Blue Earth, MN.  The partnership will focus on offering easy to use, CLIA-Waived and affordable point of care diagnostic tools for patient enrollment in pharmaceutical and biopharmaceutical clinical trials for same-day lab test results.

"With the ability to customize the configurations of twenty-two (22) different screening tests, our clients can get exactly what the clinical trial protocol requires for exclusion criteria," said Steve Karuppan, CEO of Blinded Diagnostics.  He added,  "We are also looking forward to the US launch of the AnemiaCheckTM POC Quantitative Hematocrit Test, as it will certainly have great utility for our clients' projects."

In October 2012, AnemiaCheck™ POC Quantitative Hematocrit Test was selected as a top 10 finalist for the LifeScience Alley New Technology Showcase. AnemiaCheck™, from IntraMed Diagnostics, a subsidiary of EDI, is an entirely self-contained, disposable device designed to separate red blood cells from plasma using specialized filtering materials. This innovative new product is CE marked but is not currently available in the US.

Rich Strasser, COO of Express Diagnostics said, "Blinded Diagnostics is in an excellent position to reach the global clinical trial market and provide the support for customized testing solutions along with product training."

About Express Diagnostics Int'l, Inc.
Express Diagnostics Int'l (EDI), manufactures and distributes the AnemiaCheck™ POC Quantitative Hematocrit Test, a rapid point-of-care device for anemia screening.  AnemiaCheck™ delivers quantitative hematocrit results in 15 minutes without instrumentation. Additionally, EDI manufactures and distributes DrugCheck® onsite urine, breath, and saliva screening devices. With accuracy comparable to laboratory testing, DrugCheck® onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Sold through a worldwide distributor network since 2002, DrugCheck® continues to build on its consistent growth in the on-site drug testing industry.

About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that provide same day lab test results for pharmaceutical clinical trials. Blinded Diagnostics has a successful track record of expertise in meeting large pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors.

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.